Lone Star Announces Sale of Multi-Property Real Estate Portfolio Across Texas November 10, 2025 Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Real Estate Fund VI, L.P. has successfully completed the sale of three multifamily properties across Texas which were sold to three separate buyers. Financial terms of the transaction were not disclosed. The entire portfolio totaled 606 property units: a 208-unit garden style [...]
Yubico to Accelerate Passkey Adoption with Identity Verification Partnerships, Bolstering Defense Against AI-Driven Fraud November 10, 2025 YubiKey as a Service to support IDV with HYPR and Nametag Unifying Secure Onboarding and Verified Trust
Almirall’s 2025 9M Results November 10, 2025 Almirall continues its sustained growth trajectory in 9M 2025 - delivering 12.8% net sales growth, strong dermatology performance, solid commercial execution in Europe, and further pipeline progress Sustained strong growth momentum with 12.8% Net Sales YoY increase to a total of €820.7 MM, with biologics continuing to deliver double-digit growth YoY and dermatology sales in Europe increasing 24.5% YoY further advancing Almirall´s leadership in medical dermatology. EBITDA increase of 27.1% YoY in line with expectations, reaching a total of €180.7 MM. On track to meet 2025 guidance driven by biologics growth and operational strength. Performance continues to be primarily driven by the biologics portfolio, with Ilumetri® net sales increasing 12.1% YoY (total of €170.9 MM), and Ebglyss® net sales of €75.5 MM – reflecting a more than 3x increase YoY as European markets are ramping up after launch. Solid performance of the broad dermatology product portfolio with Wynzora® growing 32.4% YoY to a total of €25.4 MM, and Klisyri® growing 22.6% YoY to a total of €20.1 MM, further enhancing Almirall’s position as trusted partner for patients and dermatologists. Continued R&D pipeline progress includes the start of the phase II study of the anti-IL-1RAP mAb, and plan to initiate three additional proof-of-concept studies over the coming 9 to 12 months.
OMRON Releases the “Medium-Term Roadmap SF 2nd Stage” November 8, 2025 OMRON (TOKYO: 6645) has announced its “Medium-Term Roadmap Shaping the Future 2nd Stage (“SF 2nd Stage”),” covering from FY2026 to FY2030, on November 7, 2025 (JST). This Roadmap presents the Group’s vision and growth strategies through 2030, which are disclosed on our corporate website. Overview of the “Medium-Term Roadmap SF 2nd Stage” Since April 2024, [...]
26th UN Tourism General Assembly kicks off in Riyadh November 7, 2025 UN Tourism marks 50 years of global cooperation as leaders from across the industry gather to shape the future of tourism. His Excellency Ahmed Al Khateeb, Minister of Tourism – “The Kingdom will play an integral part in ensuring one of the world’s most powerful generators of jobs and GDP grows in harmony with the Sustainable Development Goals.” UN Tourism Secretary-General Zurab Pololikashvili – “The UN Tourism General Assembly brings together tourism leaders from across the world to set the agenda and build a more innovative and inclusive sector. From Riyadh, we will set the agenda for tourism for the years ahead.”
Xsolla Partners With Deloitte Turkiye and Lorien Accelerator as Category Sponsor for Gaming Awards at Fast 50 Türkiye 2025 Program November 7, 2025 Celebrating Turkey’s Gaming Industry with High-Impact Sponsorship and Industry Panel
ReNew and Asian Development Bank Announce US$331 million Deal for a Large-Scale Renewable Energy Project in Andhra Pradesh November 7, 2025 Part of a US$477 million deal secured, ReNew will receive US$331 million from ADB, and the balance US$146 million will be arranged by ADB through other lenders Project expected to generate 1,641 GWh of clean energy annually, boosting grid stability and accelerating India’s energy transition
TITAN Group’s Credit Rating Improved to “BB+ with Positive Outlook” by S&P Global Ratings November 7, 2025 S&P Global Ratings has revised TITAN SA’s (Brussels:TITC) outlook to ‘Positive’ while affirming its ‘BB+’ long-term credit rating. This decision reflects TITAN Group’s continued robust financial performance and the effectiveness of its supportive financial policies. S&P’s report highlights the Group’s resilient results driven by its strong operations. The positive outlook demonstrates S&P views that they [...]
Soho House & Co Inc. Announces Third Quarter 2025 Results November 7, 2025 Soho House & Co Inc. (NYSE: SHCO) (“SHCO,” “Company,” “we” or “our”), a global membership platform that connects a vibrant, diverse, and global group of members, today announced results for the third quarter ended September 28, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107045088/en/ Third Quarter 2025 Highlights Total revenues of [...]
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights November 6, 2025 Net cash used in operating and investing activities was $40.6 million and $140.4 million for the third quarter and first nine months of 2025, respectively; quarter-end cash and restricted cash position was $331.7 million Roche to initiate the Phase 3 PARAISO clinical trial evaluating prasinezumab, a potential first-in-class anti-alpha-synuclein antibody, for early-stage Parkinson's disease by end of 2025 Novo Nordisk initiated the Phase 3 CLEOPATTRA clinical trial evaluating coramitug, a potential first-in-class amyloid depleter, for ATTR amyloidosis with cardiomyopathy Novo Nordisk to present Phase 2 results for coramitug during a late-breaking session at the American Heart Association Scientific Sessions on November 10, 2025 Bristol Myers Squibb obtained Fast Track designation from the U.S. FDA for BMS-986446 (PRX005), an anti-MTBR-tau-targeting antibody, for the treatment of Alzheimer’s disease Prothena will convene an Extraordinary General Meeting on November 19, 2025 to obtain shareholder approval on a proposal reducing share capital to create distributable reserves to support a share redemption program to be conducted in 2026 if deemed appropriate Potential to earn up to $105 million in aggregate clinical milestone payments by end of 2026 related to the advancement of coramitug for ATTR amyloidosis with cardiomyopathy by Novo Nordisk and PRX019 for neurodegenerative diseases by Bristol Myers Squibb